Boston Scientific zaps Bolt Medical in $664M intravascular lithotripsy buy
Boston Scientific is diving into the field of intravascular lithotripsy, with a $664 million deal to pick up Bolt Medical and its hardware for breaking through hardened and clogged arteri | Set to close within the first half of the year,
Boston Scientific’s Strategic Acquisition of Bolt Medical Boosts Market Potential and Growth Opportunities
Patrick Wood, an analyst from Morgan Stanley, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price
Boston Scientific to buy remaining Bolt Medical stake for up to $664M
The deal for Bolt, developer of an intravascular lithotripsy system to treat coronary and peripheral artery disease, continues Boston Scientific’s brisk run of acquisitions.
Boston Scientific makes IVL play with Bolt Medical acquisition
Boston Scientific (NYSE: BSX) announced today that it agreed to acquire intravascular lithotripsy (IVL) platform developer Bolt Medical.
Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal
Boston Scientific to acquire Bolt Medical for $600 million upfront plus milestones. Bolt's IVL platform addresses coronary and peripheral artery disease.
Boston Scientific to Buy Rest of Bolt Medical for $443 Million
Boston Scientific has agreed to acquire the rest of Bolt Medical, the developer of an intravascular-lithotripsy, or IVL, laser-based platform for the treatment of coronary and peripheral artery disease,
Boston Scientific to acquire Bolt Medical for upfront payment of $443M
Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Bolt Medical, the developer of an intravascular
Boston Scientific Surges On $900 Million Takeover Of Bolt Medical
Boston Scientific stock popped Wednesday after the medtech giant agreed to full acquire Bolt Medical for up to $900 million.
Hosted on MSN20h
Boston Scientific price target raised to $110 from $100 at Bernstein
Bernstein raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps an Outperform rating on the shares as part of a ...
Investor's Business Daily on MSN1d
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product
Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.
WBJournal1d
Boston Scientific to acquire California blood flow treatment manufacturer for up to $664M
Marlborough-based Boston Scientific has entered into a definitive agreement to acquire California-based medical equipment ...
Positive Long-Term Outlook for Boston Scientific Post-Axonics Acquisition: Buy Rating Affirmed
Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on Boston Scientific (BSX – Research Report) and keeping the price ...
Zacks.com on MSN1d
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
Boston Scientific (BSX) reachead $91.99 at the closing of the latest trading day, reflecting a +0.77% change compared to its last close.
Boston Scientific Corporation: Solid Financials And Upward Continuation
Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. Check out why ...